Avnet, Inc. (NASDAQ: AVT ) is one of the most important tech companies we never really hear much about, even though it’s one of the world’s largest electronic component distributors.I’m Emmanuel Onwusah—a financial analyst, writer, and recovering engineer. I hold FMVA® and BIDA® certifications from the Corporate Finance Institute, and I spend most of my time creating pitch decks, building models, analyzing companies, and trying to make sense of where value meets narrative. My background is in petroleum and ...

Core Viewpoint - Alvotech and Advanz Pharma announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending approval for AVT06, a proposed biosimilar to Eylea® [1][5] Company Overview - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a leader in the biosimilar space with a pipeline that includes eight disclosed candidates targeting various therapeutic areas [11][12] - Advanz Pharma is a UK-based global pharmaceutical company specializing in specialty, hospital, and rare disease medicines, with a commercial presence in over 90 countries [13] Product Details - AVT06 is intended for treating adults with neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular edema secondary to retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization [4][8] - In 2024, global sales of Eylea® were approximately US$9 billion, with one-third of these sales occurring in Europe [5] Clinical Study Results - A confirmatory clinical study (AVT06-GL-C01) demonstrated therapeutic equivalence between AVT06 and Eylea®, meeting its primary endpoint [6] Commercialization Rights - Alvotech is responsible for the development and commercial supply of AVT06, while Advanz Pharma holds exclusive commercialization rights for most European countries [5][7]

Core Viewpoint - Alvotech and Advanz Pharma have received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending approval for AVT06, a proposed biosimilar to Eylea® [1][5]. Company Overview - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a leader in the biosimilar space with a pipeline that includes eight candidates targeting various diseases [11][12]. - Advanz Pharma is a UK-based global pharmaceutical company specializing in specialty, hospital, and rare disease medicines, with a commercial presence in over 90 countries [13]. Product Details - AVT06 is intended for treating several eye disorders, including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) [4][8]. - The global sales of Eylea® were approximately US$9 billion in 2024, with one-third of these sales occurring in Europe [5]. Clinical Study Results - A confirmatory clinical study (AVT06-GL-C01) demonstrated therapeutic equivalence between AVT06 and Eylea®, meeting its primary endpoint [6]. Commercialization Rights - Alvotech is responsible for the development and commercial supply of AVT06, while Advanz Pharma holds exclusive commercialization rights in most European countries [5][7].

Core Insights - The performance of Avnet's international operations is crucial for understanding its financial strength and growth potential [1][2] - The company's total revenue for the quarter ending March 2025 was $5.32 billion, a decrease of 6% year-over-year [4] International Revenue Analysis - Asia contributed 46.70% of total revenue, amounting to $2.48 billion, with a surprising increase of 7.29% compared to expectations [5] - EMEA generated $1.56 billion, representing 29.33% of total revenue, which was an 8.58% shortfall from analyst projections [6] Future Revenue Expectations - Analysts forecast total revenue of $5.38 billion for the current fiscal quarter, a decline of 3.3% year-over-year, with Asia and EMEA expected to contribute 45.5% ($2.45 billion) and 31.6% ($1.7 billion) respectively [7] - For the entire year, total revenue is projected to be $21.98 billion, a reduction of 7.5% from the previous year, with Asia contributing 45.8% ($10.08 billion) and EMEA 30.3% ($6.65 billion) [8] Strategic Considerations - Avnet's reliance on international markets presents both opportunities and risks, making it essential to monitor international revenue trends for forecasting [9][10]

我是芯片超人花姐，入行20年，有50W+芯片行业粉丝。 有很多不方便公开发公众号的， 关于芯片买卖、 关于资源链接等， 我会分享在朋友圈 。 扫码加我本人微信 2025年的第一季度， 全球半导体销售额延续高增长 ， 但 芯片大厂业绩的 分化 现象似乎更加严 重。除了主要市场及产品带来的差异，比如AI与存储相关企业的业绩情况总体更好一些， 汽车芯 片大厂的业绩还是惨淡 。 即便 在 泛 应用 市场，芯片大厂们 也出现了不同程度的分化。 此外，4月的关税风波也影响 着 半导体产业链的各个环节，不少大厂针对关税给出了他们的预 测。 我们整理 了 2025年第1季度半导体产业链主要大厂的营收情况 ，供大家参考。 01 芯片设计（含IDM） TI：营收增长，工业市场广泛复苏 德州仪器 （TI）公布第一季度收入为 40.7 亿美元，净收入为 11.8 亿美元。 营收较去年同期增 长 11%，环比增长 2% 。除个人电子产品的季节性下滑外，所有的市场均实现了环比增长。TI 第二季度的展望是收入在 41.7 亿美元至 45.3 亿美元之间。 此外，德州仪器CEO哈维夫·伊兰（Haviv Ilan）在财报电话会上针对美国关税发 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File #1-4224 AVNET, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction (IRS Employer of in ...

Avnet (AVT) reported third-quarter fiscal 2025 earnings of 84 cents per share, beating the Zacks Consensus Estimate by 16.7%. The bottom line, however, declined 23.6% on a year-over-year basis.Net sales were $5.32 billion, which surpassed the Zacks Consensus Estimate by 0.46%. The figure, however, decreased 6% from the year-ago quarter.The company experienced declining sales across all its segments, reflecting broader market pressure. The margins were also pressured due to margin contraction across both the ...

Financial Data and Key Metrics Changes - The company achieved sales of $5.3 billion for Q3 FY2025, which is down 6% year-over-year and sequentially, but near the high end of guidance [4][14] - Adjusted EPS was $0.84, exceeding guidance, and cash flow from operations was $141 million for the quarter [4][20] - Gross margin for the quarter was 11.1%, down 78 basis points year-over-year but up 54 basis points sequentially [15] Business Line Data and Key Metrics Changes - Electronic Components sales declined 6% year-over-year and 7% sequentially, while Farnell sales decreased 10% year-over-year but increased 6% sequentially [14][15] - Farnell's operating margin improved to 3%, up approximately 200 basis points quarter-over-quarter, reflecting better sales and gross margin [19] Market Data and Key Metrics Changes - Sales in Asia increased 13% year-over-year, marking the third consecutive quarter of growth, while EMEA sales declined 24% and The Americas declined 9% year-over-year [14][15] - The industrial end market in EMEA saw slight growth, while other verticals experienced declines [7] Company Strategy and Development Direction - The company is focused on optimizing inventory composition and reducing core inventory levels where necessary [6] - The management emphasized the importance of leveraging existing customer and supplier relationships to drive growth, encapsulated in the "Power of One" strategy [11][19] - The company is actively adjusting processes to mitigate the impact of tariffs on customers and financials [12][26] Management's Comments on Operating Environment and Future Outlook - Management noted that the current environment is one of the most challenging seen in over 40 years, with complex supply chains and geopolitical uncertainties [13] - The company expects to generate positive operating cash flows in the next quarter and remains committed to balancing debt paydown with shareholder returns [22][26] Other Important Information - The company reported a gross leverage of 3.2 times and had approximately $1.2 billion of available committed borrowing capacity [22] - Book value per share increased to approximately $56, primarily due to changes in foreign currency exchange rates [23] Q&A Session Summary Question: Understanding revenue guidance for June - Management explained that the guidance reflects a cautious approach, particularly due to weak performance in Europe, with expected growth primarily from Asia [28][30] Question: Inventory expectations - Management indicated that while they aim to reduce inventory, it is strategically important and not uniformly high across all SKUs [48][52] Question: Tariff impacts on order patterns - Management noted minimal changes in order patterns due to tariffs, with only modest pull-ins observed [59][62] Question: Visibility into AI-driven components - The company has some visibility into AI-related components, particularly in Asia, but it represents a small portion of overall business [74][76]

Avnet (AVT) Q3 2025 Earnings Call April 30, 2025 12:00 PM ET Company Participants Joe Burke - VP - Investor RelationsPhil Gallagher - CEO & Member of Board of DirectorsKen Jacobson - CFO Conference Call Participants Joe Quatrochi - Director & Equity Research AnalystWilliam Stein - Managing Director/Senior Research Analyst - TechnologyWamsi Mohan - Senior Equity Research Analyst Operator Greetings and welcome to the Avnet Third Quarter Fiscal Year twenty twenty five Earnings Conference Call. At this time, pa ...

Core Insights - Avnet reported $5.32 billion in revenue for the quarter ended March 2025, reflecting a year-over-year decline of 6% [1] - The EPS for the same period was $0.84, down from $1.10 a year ago, but exceeded the consensus estimate of $0.72 by 16.67% [1] - The revenue surpassed the Zacks Consensus Estimate of $5.29 billion, resulting in a surprise of +0.46% [1] Financial Performance Metrics - Farnell sales were reported at $366.70 million, exceeding the average estimate of $338.19 million, but showing a year-over-year decline of 10.1% [4] - Electronic Components sales matched the average estimate of $4.95 billion, with a year-over-year change of -5.7% [4] - Operating income for Electronic Components was $172.20 million, above the average estimate of $166.72 million [4] - Farnell's operating income was reported at $11 million, significantly higher than the estimated $4.49 million [4] - Corporate expenses showed a loss of $30.40 million, worse than the average estimate of -$24.23 million [4] Stock Performance - Avnet shares returned +7.9% over the past month, contrasting with the Zacks S&P 500 composite's -0.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]